Dapagliflozin Post Marketing Surveillance in HF and CKD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

815 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-10

Study Completion Date

2024-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, non-interventional, single-arm multicenter study. The objectives of this study are to assess safety and effectiveness of Forxiga in a real world setting in patients who are prescribed with the study drug according to the newly approved indications in the Republic of Korea

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

NCT05225077

Renal Insufficiency, Chronic Cardiac Catheterization Percutaneous Coronary Intervention

UNKNOWN PHASE4

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

NCT05970237

Diabetes Mellitus Hypertension

RECRUITING

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

NCT06365541

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

RECRUITING PHASE4

Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

NCT05196347

Chronic Kidney Diseases

COMPLETED PHASE3

Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance

NCT02252224

Type 2 Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As part of a post-approval commitment, the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea (hereinafter "Korea") requests a study to characterize the safety in patients treated with dapagliflozin by physicians in normal clinical practice settings.

In principle, all patients treated with the product in accordance with the newly updated local prescribing information for HF and/or CKD are eligible for the enrolment in this study. Product prescription and patient enrollment will depend on physicians' medical decision as per routine clinical practice. Patient follow-up will be 12 weeks or about 24 weeks (for long-term surveillance) and patients will be recruited over a period of 4 years after the new HFrEF indication approval by the local health authorities. This is due to the requirements from the local health authorities.

The primary objective of this study is to assess the safety profile of the product in Korean adult patients with heart failure (HF) and/or chronic kidney disease (CKD) in a real world setting under the approved indication(s) in Korea.

The secondary objective of this study is to examine the effectiveness of the product in Korean patients with 1) HF and/or 2) CKD in a real world setting under the approved indication(s) in Korea.

The exploratory objective of this study is to identify patients' baseline characteristics that might be associated with the safety and effectiveness of the product when prescribed under the newly approved indication(s) in Korean patients with 1) HF and/or 2) CKD during the 12 weeks or about 24 weeks of follow-up duration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 19 years old and older
* Patients eligible for the product treatment (i.e. on-label treatment) according to the newly approved HF and/or CKD label in Korea
* Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion Criteria

* Participation in any interventional trial during the treatment with the product.
* Any off-label indications that are not in accordance with the newly approved label in Korea.
* Any contraindications for the use of the product (as described in the local prescribing information).
* Prior use of product, as per local MFDS guidance.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No